2. Search Result
Search Result
Results for "

body mass

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

1

Biochemical Assay Reagents

5

Peptides

3

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112288
    C188-9
    Maximum Cited Publications
    32 Publications Verification

    TTI-101

    		 STAT Apoptosis DNA Methyltransferase Metabolic Disease Inflammation/Immunology Cancer
    C188-9 (TTI-101) is a STAT3 inhibitor with a Kd value of 4.7 nM. C188-9 targets the SH2 domain of STAT3, blocks the processes of STAT3 ligand binding, receptor recruitment, homodimerization and phosphorylation, and regulates STAT3-mediated genes associated with tumorigenesis and radioresistance. C188-9 regulates STAT1-mediated genes related to radioresistance and reduces the activation level of STAT1. C188-9 downregulates the expression of DNMT1, enhances DAC-induced demethylation and re-expression of RASSF1A, and simultaneously potentiates the anti-tumor effect of DAC on pancreatic cancer cells. C188-9 inhibits both anchorage-dependent and anchorage-independent growth of cancer cells, induces Apoptosis, blocks the growth of tumor xenografts, and suppresses muscle atrophy. C188-9 maintains muscle mass, increases body weight and improves grip strength in tumor-bearing mice. C188-9 can be used in research related to head and neck squamous cell carcinoma, pancreatic cancer, sepsis-related skeletal muscle wasting, non-small cell lung cancer, acute myeloid leukemia and cancer cachexia .
    C188-9
  • HY-P11245A
    NN1213 acetate

    		Amylin Receptor Metabolic Disease
    NN1213 acetate, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 acetate significantly reduces food intake and fat mass. NN1213 acetate can reduce body weightin diet-induced obese rats. NN1213 acetate can be used for the research of obesity .
    NN1213 acetate
  • HY-N2840
    Allitol
    1 Publications Verification

    Allodulcitol

    		 Others Metabolic Disease
    Allitol (Allodulcitol) is an orally active rare sugar alcohol found in Itea virginica L, Tylopilus plumbeoviolaceus. Allitol has anti-obesity and hypoglycaemic activities. Allitol reduces carcass and total body fat mass, increases cecal weight, surface area, and short-chain fatty acid production, and upregulates cecal microbial enzymes linked to butyrate metabolism. Allitol can be used for the researches of obesity and diabetes .
    Allitol
  • HY-P11245
    NN1213

    		Amylin Receptor Metabolic Disease
    NN1213, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 significantly reduces food intake and fat mass. NN1213 can reduce body weightin diet-induced obese rats. NN1213 can be used for the research of obesity .
    NN1213
  • HY-117787
    TUG-905

    		Free Fatty Acid Receptor Neurological Disease Metabolic Disease
    TUG-905 is a potent GPR40 agonist with an pEC50 value of 7.03. TUG-905 increases hypothalamic cell proliferation and survival. TUG-905 reduces body mass and increases the POMC mRNA expression .
    TUG-905
  • HY-120872
    AJS1669 free acid

    		Glycosyltransferase Metabolic Disease
    AJS1669 free acid is a potent and orally available glycogen synthase (GS) activator. AJS1669 improves glucose metabolism and reduces body fat mass in mice[1].
    AJS1669 free acid
  • HY-W127851
    CLA

    Cypridina luciferin analog

    		 Biochemical Assay Reagents Others Cancer
    CLA, or conjugated linoleic acid, is a polyunsaturated fatty acid that occurs naturally in a variety of animal products, such as meat and dairy. It has several potential benefits for human health, including the ability to reduce body fat mass, improve insulin sensitivity, and reduce inflammation. CLA has been extensively studied for its effects on weight loss and muscle growth, as well as its potential role in preventing chronic diseases such as heart disease and cancer. Additionally, it can be taken as a dietary supplement in capsule form.
    CLA
  • HY-P11262
    GUB021794

    		GLP Receptor Metabolic Disease
    GUB021794 is a potent and highly selective glucagon-like peptide-1 receptor (GLP-1R) agonist developed using the streaMLine platform with an EC50 value of 18 pM. GUB021794 has a very weak activity against SCTR, with an EC50 value of 190 nM. GUB021794 can significantly reduce the body weight, food intake, and total fat mass of mice in a diet-induced obesity (DIO) model. GUB021794 can be used for research on obesity/diabetes .
    GUB021794
  • HY-W552832
    10-Oxooctadecanoic acid

    		Endogenous Metabolite Metabolic Disease
    10-Oxooctadecanoic acid is an oxo fatty acid that can be isolated from mature adipocere in human remains that have been deceased for 6 months. 10-Oxooctadecanoic acid, together with monohydroxy fatty acids, promotes the enhancement and stabilization of adipocere formation .
    10-Oxooctadecanoic acid
  • HY-Y1150
    Pivalic acid

    Trimethylmethanecarboxylic acid; Versatic 5 acid; tert-Pentanoic acid

    		 Antibiotic Inflammation/Immunology
    Pivalic acid (Trimethylmethanecarboxylic acid) is a carboxylic acid. Pivalic acid induces Carnitine deficiency. Pivalic acid conjugated with Antibiotics, such as Pivmecillinam (HY-B0810) and Pivampicillin (HY-119011), are used in urinary tract infection. Pivalic acid can be used in physical exercise research .
    Pivalic acid
  • HY-U00353
    MCHR1 antagonist 1

    		MCHR1 (GPR24) Metabolic Disease Endocrinology
    MCHR1 antagonist 1 is a selective antagonist of melanin concentrating hormone-1 (MCH1) receptor, with a Kb of 1 nM and a Ki of 4 nM at human MCH1, and may be used to reduce the body mass.
    MCHR1 antagonist 1
  • HY-19656
    HMR1426

    		Biochemical Assay Reagents Metabolic Disease
    HMR1426 is an orally active, potent gastric emptying inhibitor. HMR1426 reduces food intake and the rate of gastric emptying, decreases body weight and fat mass and shows an anorectic potential in rats. HMR1426 has the potential for obesity research .
    HMR1426
  • HY-161985
    PPARγ-IN-3

    		PPAR Metabolic Disease
    PPARγ-IN-3 (compound 9ga) is a potent and orally active PPARγ inhibitor. PPARγ-IN-3 reduces triglyceride (TG) accumulation with low cytotoxicity. PPARγ-IN-3 preventes the excessive growth of body weight and lessened fat mass as well as liver mass, decreases lipid accumulation in the liver and blood. PPARγ-IN-3 has the potential for the research of diet-induced obesity .
    PPARγ-IN-3
  • HY-N2840S
    Allitol-13C

    Allodulcitol-13C

    		 Isotope-Labeled Compounds Metabolic Disease
    Allitol (Allodulcitol)- 13C is the 13C labeled Allitol (HY-N2840). Allitol is an orally active rare sugar alcohol found in Itea virginica L, Tylopilus plumbeoviolaceus. Allitol has anti-obesity and hypoglycaemic activities. Allitol reduces carcass and total body fat mass, increases cecal weight, surface area, and short-chain fatty acid production, and upregulates cecal microbial enzymes linked to butyrate metabolism. Allitol can be used for the researches of obesity and diabetes .
    Allitol-13C
  • HY-N2840R
    Allitol (Standard)

    Allodulcitol (Standard)

    		 Reference Standards Metabolic Disease
    Allitol (Allodulcitol) (Standard) is the analytical standard of Allitol (HY-N2840). This product is intended for research and analytical applications. Allitol is an orally active rare sugar alcohol found in Itea virginica L, Tylopilus plumbeoviolaceus. Allitol has anti-obesity and hypoglycaemic activities. Allitol reduces carcass and total body fat mass, increases cecal weight, surface area, and short-chain fatty acid production, and upregulates cecal microbial enzymes linked to butyrate metabolism. Allitol can be used for the researches of obesity and diabetes .
    Allitol (Standard)
  • HY-11032
    SM-350300

    		Others Metabolic Disease
    SM-350300 is a glucoprotein. SM-350300 stimulates lipolysis in white adipocytes by activating the cyclic AMP (cAMP) pathway, and upregulates the expression of lipolytic enzymes and uncoupling proteins (UCP1, UCP3) in brown adipose tissue (BAT) and white adipose tissue (WAT). SM-350300 reduces body weight by decreasing carcass fat while increasing lean muscle mass in metabolic disorder models. SM-350300 can be used for the study of metabolic disorders including obesity, type 2 diabetes, and cachexia .
    SM-350300
  • HY-180642
    THR-β modulator-3

    		Thyroid Hormone Receptor Metabolic Disease
    THR-β modulator-3 (Compound 75-2) is a THR-β modulator. THR-β modulator-3reduces total fat mass, body weight. THR-β modulator-3 improves obesity .
    THR-β modulator-3
  • HY-186096
    LP-856866

    		ACSL Family GLP Receptor Metabolic Disease
    LP-856866 is an orally active ACSL5 inhibitor, with IC50 values of 8 nM and 4 nM against mouse and human ACSL5, respectively, and IC50 values of 6 nM and 17 nM against mouse and human ACSL1, respectively. LP-856866 induces delayed gastric emptying, promotes GLP-1 release, reduces food intake, decreases body weight and body fat mass, preserves lean body mass, improves glucose homeostasis, enhances insulin sensitivity, reduces hepatic lipid accumulation, and lowers serum triglyceride and total cholesterol levels. LP-856866 is applicable to research on diet-induced obesity .
    LP-856866
  • HY-P11587
    BGM1812

    		Amylin Receptor CGRP Receptor Metabolic Disease
    BGM1812 is a dual agonist of amylin (hAMY3R) (EC50 = 0.627 nM) and CGRP Receptor (hCTR) (EC50 = 2.27 nM). BGM1812 achieves weight loss, increases the proportion of lean body mass, and reduces fat mass in diet-induced obese (DIO) rats. BGM1812 is applicable to research related to obesity .
    BGM1812
  • HY-P11610
    KBP-089

    		Amylin Receptor CGRP Receptor Metabolic Disease
    KBP-089 is a dual Amylin and Calcitonin Receptor agonist. KBP-089 reduces body weight, decreases adipose tissue mass and improves glucose tolerance in obese rats. KBP-089 also eliminates lipid accumulation in the liver and muscle, and ameliorates glycemic homeostasis and insulin sensitivity. KBP-089 is applicable to the research of diseases such as obesity and type 2 diabetes .
    KBP-089
  • HY-14341
    E-6837

    		5-HT Receptor Metabolic Disease
    E-6837 is a selective and orally active 5-HT6 receptor ligand. E-6837 demonstrates partial agonism at a presumably silent rat 5-HT6 receptor and full agonism at a constitutively active human 5-HT6 receptor by monitoring the cAMP signaling pathway. E-6837 induces hypophagia, reduces fat mass and body weight, and improves glycemic control. E-6837 can be used for the research of obesity .
    E-6837
  • HY-17604
    Bexagliflozin
    1 Publications Verification

    EGT1442; EGT0001442; THR-1442

    		 SGLT Cardiovascular Disease Metabolic Disease
    Bexagliflozin (EGT1442) is an orally active and selective SGLT2 inhibitor with IC50 values of 0.002 μM and 5.6 μM for SGLT2 and SGLT1, respectively. Bexagliflozin selectively inhibits SGLT2-mediated sodium-dependent glucose uptake. Bexagliflozin induces saturable urinary glucose excretion in normal rats and dogs. Bexagliflozin reduces blood glucose and HbA1c levels in db/db mice without affecting body mass or insulin level. Bexagliflozin can be used for the research of type 2 diabetes mellitus, hypertensive stroke .
    Bexagliflozin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: